SciBase Nevisense Selected as Primary Endpoint in NIH Skin Barrier Study

SciBase Holding AB announced on Wednesday, October 15, 2026, that its Nevisense platform and electrical impedance spectroscopy (EIS) technology have been selected as the primary endpoint for an NIH-led skin barrier investigation.

### Money Play Research validation via federal health initiatives underscores the clinical utility of medical technology platforms, though no specific investable equity tickers are tied to this announcement outside of SciBase's local listing.

## Catalyst Analysis: NIH Clinical Study Selection The National Institutes of Health, in collaboration with the Swiss Institute of Allergy and Asthma Research, initiated the THREAT study (Testing Harms Related to Exposure to Allergenic Toxins). The research utilizes SciBase Nevisense and its electrical impedance spectroscopy technology as a primary endpoint to quantify how environmental exposures impact skin barrier dysfunction across 80 healthy volunteers.

## Technical Analysis & Key Risk Watch

The study design—detailed in the peer-reviewed journal Allergy under the title "Exploring the Link Between Environmental Exposures and Disease via Direct Challenge"—assesses everyday irritants, including sodium lauryl sulfate, synthetic textiles, and detergents. EIS transmits electrical signals at varying frequencies to measure opposition to flow, serving as an objective biomarker alongside molecular, microbiome, and inflammatory metrics.

## Impact on Medical Technology and Dermatology Research This deployment reinforces the scientific validity of EIS technology beyond traditional detection use cases. By integrating into a structured federal research protocol, SciBase positions its point-of-care hardware for potential broader applications across dermatology, cosmetic research, and skin care product development.